×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Colorectal Cancer

Feature Video
Colorectal cancer is one of the more commonly diagnosed cancers among both men and women today. Despite the fact that it most exclusively affects older persons, colorectal cancer is continuing to be diagnosed in younger and younger patients. CURE Connections wants to answer any questions you might have when it comes to managing colorectal cancer. This program includes information as shared by an expert physician, and personal accounts from patients and their caretakers who have dealt with colorectal cancer.
Luis A. Diaz, M.D.
Luis A. Diaz, M.D., head of the division of Solid Tumors at Memorial Sloan Kettering Cancer Center, discusses response rates in patients with microsatellite instability-high (MSI-H) or NTRK fusion gastrointestinal (GI) cancers.
Danielle Bucco

“The very exciting field of checkpoint inhibitors is still evolving, and we are trying to understand where they fit in the world of CRC therapy,” said McCollum, a hematologist and medical oncologist at Texas Oncology.
Katie Kosko
A recent study found that the cost to patients with breast, lung and colorectal cancers treated in the hospital outpatient setting was nearly $8,000 more than those treated in the community setting.
Colorectal Cancer Alliance
National non-profit begins a new chapter revealing new name, logo, and inclusive mission.
Katie Kosko
Nutrition plays a crucial role in the lives of people with cancer. But more than a million people suffering from the disease in the United States also endure a wasting syndrome called cachexia.
Martin D. Berger, M.D.
Researchers might be on to a new biomarker for patients with colorectal cancer, says Martin D. Berger, M.D., oncologist at the University of Southern California.
Angelica Welch
We’re moving into a new era of understanding with genetic abnormalities in colorectal cancer (CRC) as researchers continue to investigate tumor sidedness and the role of microsatellite instability (MSI) testing.
Jason M. Broderick

Opdivo (nivolumab) was granted approval by the Food and Drug Administration (FDA) for the treatment of both adult and pediatric patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) who have progressed following treatment with a fluoropyrimidine, oxaliplatin and irinotecan.
Brielle Urciuoli
Holocaust survivors had higher rates of lung and colorectal cancer, according to a recent study.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable